PuraPharm Corporation Limited (HKG:1498)
Hong Kong
· Delayed Price · Currency is HKD 0.330
+0.020 (6.45%)
At close: Mar 10, 2026
PuraPharm Corporation Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 346.76 | 382.09 | 406.86 | 448.07 | 659.59 | 601.82 | Upgrade
|
| Revenue Growth (YoY) | -17.32% | -6.09% | -9.20% | -32.07% | 9.60% | -13.52% | Upgrade
|
| Cost of Revenue | 159.76 | 176.95 | 190.23 | 185.37 | 236.24 | 231.87 | Upgrade
|
| Gross Profit | 187 | 205.14 | 216.63 | 262.7 | 423.35 | 369.95 | Upgrade
|
| Selling, General & Admin | 217.75 | 224.39 | 263.18 | 315.3 | 388.46 | 364 | Upgrade
|
| Other Operating Expenses | -4.04 | 0.62 | 3.93 | 5.11 | 2.73 | 18.95 | Upgrade
|
| Operating Expenses | 214.72 | 224.01 | 269.83 | 330.95 | 408.22 | 393.77 | Upgrade
|
| Operating Income | -27.71 | -18.86 | -53.2 | -68.25 | 15.14 | -23.82 | Upgrade
|
| Interest Expense | -19.64 | -23.71 | -27.41 | -24.18 | -27.03 | -26.83 | Upgrade
|
| Interest & Investment Income | 0.07 | 0.35 | 0.29 | 0.48 | 0.36 | 0.46 | Upgrade
|
| Earnings From Equity Investments | -0.16 | -0.31 | -0.15 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -1.13 | -0.87 | -0.41 | -0.08 | 0.71 | 4 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.11 | 4.49 | 9.24 | 12.25 | 1.22 | 2.56 | Upgrade
|
| EBT Excluding Unusual Items | -42.46 | -38.93 | -71.63 | -79.79 | -9.6 | -43.64 | Upgrade
|
| Impairment of Goodwill | - | - | -3.05 | - | -67.35 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.06 | 1.44 | -0 | 0.17 | 0.3 | 0.06 | Upgrade
|
| Gain (Loss) on Sale of Assets | 9.31 | 11.12 | 2.02 | 1.73 | -0.01 | -2.11 | Upgrade
|
| Asset Writedown | -2.77 | -2.77 | -29.66 | -41.3 | -48.66 | 20.11 | Upgrade
|
| Other Unusual Items | - | - | - | - | 8.12 | 65.8 | Upgrade
|
| Pretax Income | -34.87 | -29.14 | -102.31 | -119.18 | -117.19 | 40.22 | Upgrade
|
| Income Tax Expense | 3.69 | 6.3 | 3.77 | 1.03 | 4.69 | 8.51 | Upgrade
|
| Earnings From Continuing Operations | -38.56 | -35.44 | -106.08 | -120.21 | -121.88 | 31.71 | Upgrade
|
| Net Income | -38.56 | -35.44 | -106.08 | -120.21 | -121.88 | 31.71 | Upgrade
|
| Net Income to Common | -38.56 | -35.44 | -106.08 | -120.21 | -121.88 | 31.71 | Upgrade
|
| Shares Outstanding (Basic) | 395 | 395 | 395 | 395 | 394 | 371 | Upgrade
|
| Shares Outstanding (Diluted) | 395 | 395 | 395 | 395 | 394 | 371 | Upgrade
|
| Shares Change (YoY) | - | - | 0.12% | 0.22% | 6.01% | 42.44% | Upgrade
|
| EPS (Basic) | -0.10 | -0.09 | -0.27 | -0.30 | -0.31 | 0.09 | Upgrade
|
| EPS (Diluted) | -0.10 | -0.09 | -0.27 | -0.30 | -0.31 | 0.09 | Upgrade
|
| Free Cash Flow | 79.16 | 89.18 | 60.43 | 67.68 | -17.61 | 43.81 | Upgrade
|
| Free Cash Flow Per Share | 0.20 | 0.23 | 0.15 | 0.17 | -0.04 | 0.12 | Upgrade
|
| Gross Margin | 53.93% | 53.69% | 53.24% | 58.63% | 64.18% | 61.47% | Upgrade
|
| Operating Margin | -7.99% | -4.94% | -13.08% | -15.23% | 2.30% | -3.96% | Upgrade
|
| Profit Margin | -11.12% | -9.28% | -26.07% | -26.83% | -18.48% | 5.27% | Upgrade
|
| Free Cash Flow Margin | 22.83% | 23.34% | 14.85% | 15.10% | -2.67% | 7.28% | Upgrade
|
| EBITDA | 7.73 | 14.63 | -29.15 | -42.11 | 40.12 | -0.46 | Upgrade
|
| EBITDA Margin | 2.23% | 3.83% | -7.17% | -9.40% | 6.08% | -0.08% | Upgrade
|
| D&A For EBITDA | 35.45 | 33.49 | 24.05 | 26.14 | 24.98 | 23.37 | Upgrade
|
| EBIT | -27.71 | -18.86 | -53.2 | -68.25 | 15.14 | -23.82 | Upgrade
|
| EBIT Margin | -7.99% | -4.94% | -13.08% | -15.23% | 2.30% | -3.96% | Upgrade
|
| Effective Tax Rate | - | - | - | - | - | 21.15% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.